These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39215767)

  • 1. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).
    Al-Lehebi RO; Al Ahmad M; Maturu VN; Mesa AG; Mahboub B; Garcia E; Fernandez P; Soares C; Abreu G; Dos Santos D; Queiroz J; Raimondi A; Laucho-Contreras M; Noibi S; Levy G; Bavbek S
    Adv Ther; 2024 Nov; 41(11):4008-4031. PubMed ID: 39215767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S
    Eur Ann Allergy Clin Immunol; 2024 Jul; 56(4):169-175. PubMed ID: 36927725
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
    Harrison T; Canonica GW; Chupp G; Lee J; Schleich F; Welte T; Valero A; Gemzoe K; Maxwell A; Joksaite S; Yang S; Howarth P; Van Dyke MK
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32817259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world unified airway benefits of mepolizumab: Effectiveness in patients with asthma and comorbid nasal polyps.
    Bernstein JA; Silver J; Packnett E; Lew CR; Robles Y; Deb A
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):422-429.e2. PubMed ID: 38972449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
    Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
    J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma.
    Pilette C; Canonica GW; Chaudhuri R; Chupp G; Lee FE; Lee JK; Almonacid C; Welte T; Alfonso-Cristancho R; Jakes RW; Maxwell A; Price RG; Howarth P
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2646-2656. PubMed ID: 35753668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
    Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
    Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.
    Renner A; Marth K; Patocka K; Idzko M; Pohl W
    Pulm Pharmacol Ther; 2020 Oct; 64():101946. PubMed ID: 32949705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis.
    Silver J; Molfino N; Bogart M; Packnett ER; McMorrow D; Wu J; Hahn B
    Clin Ther; 2021 Dec; 43(12):2064-2073. PubMed ID: 34893348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland.
    Koistinen V; Kauppi P; Idänpään-Heikkilä J; Veijalainen L; Iso-Mustajärvi I; Ylisaukko-Oja T; Mehtälä J; Viinanen A; Kilpeläinen M
    J Asthma; 2022 Dec; 59(12):2375-2385. PubMed ID: 35094632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.